Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.

PubMed  Google Scholar 

Ocker L, Abu Rached N, Seifert C, Scheel C, Bechara FG. Current medical and surgical treatment of hidradenitis suppurativa—a comprehensive review. J Clin Med. 2022;11(23):7240.

CAS  PubMed  PubMed Central  Google Scholar 

Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–58.

CAS  PubMed  Google Scholar 

Caccavale S, Tancredi V, Boccellino MP, Babino G, Fulgione E, Argenziano G. Hidradenitis suppurativa burdens on mental health: a literature review of associated psychiatric disorders and their pathogenesis. Life (Basel). 2023;13(1):189.

CAS  PubMed  Google Scholar 

Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366–76.

PubMed  Google Scholar 

Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5(5):330–4.

PubMed  PubMed Central  Google Scholar 

Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545–52.

PubMed  PubMed Central  Google Scholar 

Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118–22.

PubMed  Google Scholar 

Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis. Biomed Dermatol. 2020;4:2.

Google Scholar 

Naik HB, Paul M, Cohen SR, Alavi A, Suàrez-Fariñas M, Lowes MA. Distribution of self-reported hidradenitis suppurativa age at onset. JAMA Dermatol. 2019;155(8):971–3.

PubMed  PubMed Central  Google Scholar 

Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760–4.

PubMed  PubMed Central  Google Scholar 

Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2018;32(10):1784–90.

CAS  PubMed  Google Scholar 

Gotesman RD, Choi C, Alavi A. Hidradenitis suppurativa in East and Southeast Asian populations: a systematic review and meta-analysis. Int J Dermatol. 2021;60(11):e433–9.

PubMed  Google Scholar 

Shih T, Seivright JR, McKenzie SA, Harview CL, Truong AK, Shi VY, et al. Gender differences in hidradenitis suppurativa characteristics: a retrospective cohort analysis. Int J Womens Dermatol. 2021;7(5 Part B):672–4.

PubMed  PubMed Central  Google Scholar 

Serrano L, Ulschmid C, Szabo A, Roth G, Sokumbi O. Racial disparities of delay in diagnosis and dermatologic care for hidradenitis suppurativa. J Natl Med Assoc. 2022;114(6):613–6.

PubMed  Google Scholar 

D'Onghia M, Malvaso D, Galluccio G, Antonelli F, Coscarella G, Rubegni P, et al. Evidence on hidradenitis suppurativa as an autoinflammatory skin disease. J Clin Med. 2024;13(17):5211.

CAS  PubMed  PubMed Central  Google Scholar 

Verma SS, Sharma K, Chhabra S. Pathogenesis of hidradenitis suppurativa: an immunological perspective. Indian J Dermatol. 2023;68(3):296–300.

PubMed  PubMed Central  Google Scholar 

Shah A, Alhusayen R, Amini-Nik S. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res. 2017;66(11):931–45.

CAS  PubMed  Google Scholar 

van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292–8.

PubMed  Google Scholar 

Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121–34.

CAS  PubMed  PubMed Central  Google Scholar 

Moran B, Sweeney CM, Hughes R, Malara A, Kirthi S, Tobin AM, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J Investig Dermatol. 2017;137(11):2389–95.

CAS  PubMed  Google Scholar 

Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670–5.

CAS  PubMed  Google Scholar 

Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I, et al. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study. Exp Dermatol. 2022;31(10):1522–32.

CAS  PubMed  PubMed Central  Google Scholar 

van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(4):1150–61.

PubMed  Google Scholar 

Snyder CL, Chen SX, Porter ML. Obstacles to early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol. 2023;16:1833–41.

CAS  PubMed  PubMed Central  Google Scholar 

Rathod U, Prasad PN, Patel BM, Patel B, Patel C, Gandhi SK, et al. Hidradenitis suppurativa: a literature review comparing current therapeutic modalities. Cureus. 2023;15(8): e43695.

PubMed  PubMed Central  Google Scholar 

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–34.

CAS  PubMed  Google Scholar 

Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–61.

CAS  PubMed  Google Scholar 

Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504–19.

CAS  PubMed  Google Scholar 

Kirby JS. Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema. J Invest Dermatol. 2021;141(5):1136–8.

CAS  PubMed  Google Scholar 

Flood KS, Porter ML, Kimball AB. A visit guide for hidradenitis suppurativa-managing a complex disease in a busy clinic. J Am Acad Dermatol. 2021;84(3):e155–60.

PubMed  Google Scholar 

Macklis PC, Tyler K, Kaffenberger J, Kwatra S, Kaffenberger BH. Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients. Arch Dermatol Res. 2022;314(3):293–300.

PubMed  Google Scholar 

Moltrasio C, Tricarico PM, Moura RR, Brandão L, Crovella S, Marzano AV. Clinical and molecular characterization of hidradenitis suppurativa: a practical framework for novel therapeutic targets. Dermatology. 2023;239(5):836–9.

CAS  PubMed  Google Scholar 

Lavda AC, Webb TL, Thompson AR. A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions. Br J Dermatol. 2012;167(5):970–9.

CAS  PubMed  Google Scholar 

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90.

PubMed  PubMed Central  Google Scholar 

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101.

PubMed  PubMed Central  Google Scholar 

Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44.

CAS  PubMed  Google Scholar 

Bertolotti A, Sbidian E, Join-Lambert O, Bourgault-Villada I, Moyal-Barracco M, Perrot P, et al. Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the